CHD

Business Context and Reporting Period

Company: Church & Dwight Co., Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 1, 2005 (Second Quarter)
Business Overview: The Company operates in three segments: Consumer Domestic (deodorizing, cleaning, laundry, personal care), Consumer International (primarily personal care), and Specialty Products Division (SPD). A significant portion of the current period's results reflects the full consolidation of Armkel, LLC, following the acquisition of the remaining 50% interest in May 2004.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 29.6% in Q2 and 35.4% YTD compared to the prior year. The majority of this increase ($85.5 million in Q2; $208.1 million YTD) is attributable to the inclusion of former Armkel products, which were previously accounted for under the equity method.
• Margin Expansion: Gross margin improved to 38.2% from 35.1% in Q2 2004. This is largely due to the higher-margin Armkel product mix and the absence of the $4.1 million inventory step-up charge recorded in 2004. However, margins on legacy products faced pressure from rising oil-based raw material and packaging costs.
• Expense Increases: Marketing expenses rose $14.9 million in Q2 and SG&A expenses rose $15.9 million, primarily driven by the consolidation of Armkel operations. SG&A also included $3.8 million in intangible asset impairment charges.
• Debt Reduction: Total debt decreased from $858.7 million at year-end 2004 to $770.9 million, driven by $100 million in voluntary payments on the Term B Loan.

Outlook, Risks, and Management Commentary

• Debt Redemption: The Company issued a Notice of Intention to Redeem all remaining 9 1/2% Senior Subordinated Notes due 2009 on August 15, 2005, at a price of 104.75% of principal. Approximately $7 million in cash will be used for this redemption.
• Regulatory Risks: The Company faces potential regulatory changes regarding the spermicide nonoxynol-9 (N-9) in condoms. The FDA is expected to issue guidance on labeling. While the Company has implemented interim labeling changes, future restrictions could impact financial results.
• Cost Pressures: Rising costs for energy-based raw materials and packaging are impacting margins. The Company is implementing pricing increases (already applied to condoms, cat litter, and some laundry products) and cost reduction programs to offset these increases.
• Accounting Changes: The Company is evaluating the impact of SFAS No. 123R (Share-Based Payment), effective January 1, 2006, which will require fair-value recognition of stock-based compensation.
• Liquidity: Adjusted EBITDA for the first six months was $156.1 million. The leverage ratio (2.65x) and interest coverage ratio (5.61x) remain well within the limits of the Company's credit facility.

Investor Verification Checklist

• Armkel Integration: Verify the sustainability of the revenue and margin growth attributed to the Armkel acquisition once the full-year comparison is available.
• Commodity Costs: Monitor the effectiveness of price increases and cost-reduction programs in offsetting rising oil and raw material costs.
• Regulatory Impact: Track FDA guidance on N-9 labeling and potential market reaction to the interim labeling changes.
• Debt Service: Confirm the execution of the $7 million note redemption and the impact on future interest expense.
• Working Capital: Observe the anticipated decline in working capital in the second half of 2005, specifically regarding accounts receivable.